Solid Earnings May Not Tell The Whole Story For Lushang Freda PharmaceuticalLtd (SHSE:600223)
Solid Earnings May Not Tell The Whole Story For Lushang Freda PharmaceuticalLtd (SHSE:600223)
The stock price didn't jump after Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) posted decent earnings last week. We think that investors might be worried about some concerning underlying factors.
上週,福瑞達醫藥股份有限公司(SHSE:600223)發佈了可觀的收益,但股價並未上漲。我們認爲投資者可能擔心一些令人關注的潛在因素。
How Do Unusual Items Influence Profit?
非常規項目如何影響利潤?
For anyone who wants to understand Lushang Freda PharmaceuticalLtd's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥26m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. If Lushang Freda PharmaceuticalLtd doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
對於任何想要了解福瑞達醫藥有限公司超越法定數字的利潤的人來說,值得注意的是,在過去十二個月中,法定利潤中獲得了2600萬人民幣的飛凡項目收益。儘管盈利增加總是好事,但來自飛凡項目的大量貢獻有時會減弱我們的熱情。當我們分析全球絕大多數上市公司時,我們發現重大的飛凡項目往往不會重複出現。這正如您所期望的那樣,因爲這些提振被描述爲「飛凡」。如果福瑞達醫藥有限公司看不到這種貢獻再現,那麼其他一切相等的情況下,我們預計其利潤會在今年下降。
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。
Our Take On Lushang Freda PharmaceuticalLtd's Profit Performance
我們對福瑞達醫藥有限公司的盈利表現看法
Arguably, Lushang Freda PharmaceuticalLtd's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Lushang Freda PharmaceuticalLtd's statutory profits are better than its underlying earnings power. But the happy news is that, while acknowledging we have to look beyond the statutory numbers, those numbers are still improving, with EPS growing at a very high rate over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example - Lushang Freda PharmaceuticalLtd has 1 warning sign we think you should be aware of.
可以說,福瑞達製藥有限公司的法定收入受到提高利潤的飛凡項目扭曲。正因爲如此,我們認爲福瑞達製藥有限公司的法定利潤可能優於其潛在盈利能力。但令人高興的消息是,儘管我們承認必須超越法定數字,但這些數字仍在改善,EPS在過去一年增長得非常快。當然,在分析其盈利方面時,我們只是觸及了表面;人們還可以考慮利潤率、預測增長和投資回報率,以及其他因素。考慮到這一點,除非我們充分了解風險,否則我們不會考慮投資股票。例如 - 福瑞達製藥有限公司有一個警告標誌,我們認爲您應該意識到。
Today we've zoomed in on a single data point to better understand the nature of Lushang Freda PharmaceuticalLtd's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
今天,我們把焦點放在一個單一數據點上,以更好地了解福瑞達製藥有限公司利潤的性質。但有許多其他方法可以幫助你了解一家公司。有些人認爲高淨資產回報率是一個高質量企業的良好標誌。也許需要您做一些研究,您可能會發現這個免費的公司收藏具有較高淨資產回報率,或者這個擁有重要內部持股的股票清單很有用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。